{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["86(3)"],"submitter":["Millan B"],"funding":["This study was supported by the Intramural Research Program of the National Institutes of Health (NIH)."],"pubmed_abstract":["<h4>Introduction</h4>Neoadjuvant intense androgen deprivation therapy (ADT) with androgen receptor signaling inhibitors (ARSIs) has shown pathologic complete responses (pCR) in prostate cancer (PCa), but long-term survival outcomes remain unclear. This study evaluates the durability of response following neoadjuvant ADT plus enzalutamide before robot-assisted radical prostatectomy (RARP) and lymph node dissection.<h4>Methods</h4>We conducted a secondary analysis of an open-label feasibility trial enrolling men with NCCN intermediate-, high-, very high-risk localized and regional PCa treated with 6 months of neoadjuvant ADT and enzalutamide. Factors associated with biochemical recurrence (BCR) and metastases were evaluated using appropriate univariable statistical tests, and BCR-, metastasi"],"journal":["The Prostate"],"pagination":["365-371"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12789907"],"repository":["biostudies-literature"],"pubmed_title":["Long-Term Follow-Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial."],"pmcid":["PMC12789907"],"pubmed_authors":["Turkbey B","Blachman-Braun R","Gurram S","Saini J","Pinto PA","Millan B","Loebach L","Patel M","Karzai F","Pramod N"],"additional_accession":[]},"is_claimable":false,"name":"Long-Term Follow-Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial.","description":"<h4>Introduction</h4>Neoadjuvant intense androgen deprivation therapy (ADT) with androgen receptor signaling inhibitors (ARSIs) has shown pathologic complete responses (pCR) in prostate cancer (PCa), but long-term survival outcomes remain unclear. This study evaluates the durability of response following neoadjuvant ADT plus enzalutamide before robot-assisted radical prostatectomy (RARP) and lymph node dissection.<h4>Methods</h4>We conducted a secondary analysis of an open-label feasibility trial enrolling men with NCCN intermediate-, high-, very high-risk localized and regional PCa treated with 6 months of neoadjuvant ADT and enzalutamide. Factors associated with biochemical recurrence (BCR) and metastases were evaluated using appropriate univariable statistical tests, and BCR-, metastasi","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-15T06:17:04.538Z","creation":"2026-06-30T03:19:24.659Z"},"accession":"S-EPMC12789907","cross_references":{"pubmed":["41241930"],"doi":["10.1002/pros.70093"]}}